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Summary
Background: Worldwide coronary heart disease (CHD) is estimated to be the leading
cause of death. Current knowledge about prevention of CHD is mainly derived from
developed countries. Therefore, this study aimed to ﬁnd out the association of CHD
with ratios of different lipoproteins and apolipoproteins, LDL particle size, as well
as different traditional risk factors in Asian Indian population in Eastern part of
India.
Methods: Case—control study of 100 patients with CHD and 98 healthy controls were
age and sex matched. After clinical evaluation, blood samples were collected for
biochemical assays.
Results: Multivariate logistic regression analysis found apoB (OR 2.96; 95% CI
1.02—8.54), apoB/HDL-c (OR 4.14; 95% CI 1.33—12.83), nonHDL-c (OR 5.41; 95% CI
2.08—14.10), apoB/apoAI (OR 6.64; 95% CI 2.37—18.57), and LDL particle size (9.59;
95% CI 2.92—31.54) were independently associated with CHD. Area under the ROC
curves derived from the model (AUROC 0.947; 95% CI 0.916—0.977) are signiﬁcantly
higher than any other variables.
Conclusions: Findings from the multivariate analysis, apoB, apoB/HDL-c, nonHDL-c,
apoB/apoAI, and LDL particle size are potent indicators and useful for diagnosis of
predisposed CHD.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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ntroduction
oronary heart diseases (CHD) account for a large
roportion of all deaths and disability worldwide.
oronary artery disease (CAD) [1] and ischemic
eart disease [2] are the synonyms of CHD. The
revalence of CHD is known to be high among peo-
le of Asian Indian origin. Indians settled in the
SA have a four fold higher prevalence of CHD than
aucasian Americans and six fold higher hospitaliza-
ions than Chinese Americans [3]. Rates are rising
n India, and by 2015 CHD has been predicted to
ank ﬁrst among the causes of death in the Indian
opulation [4]. The high tendency to develop pre-
ature and accelerated CHD in Asian Indians is only
artially explained by the presence of conventional
isk factors such as insulin resistance and abdominal
besity [5], etc. Among the conventional risk fac-
ors, elevated levels of serum total cholesterol (TC)
6], low density lipoprotein cholesterol (LDL-c) [7],
riglycerides (TG) [8,9], apolipoprotein B (apoB)
10], and lower levels of high density lipoprotein
holesterol (HDL-c) [11,12] and apolipoprotein AI
apoAI) [13] are the well known and established
iomarker in CHD. Small dense LDL is considered to
romote atherosclerosis in CHD because of its low
fﬁnity for LDL receptors [14] and susceptibility to
xidative modiﬁcation [15].
Since the number of deaths in the Indian popula-
ion due to CHD have drastically increased, it is not
urprising that the medical fraternity is now focus-
ng more on ﬁnding preventive measures. Current
nowledge about the prevention of CHD and car-
iovascular disease is mainly derived from studies
one in populations of European and American ori-
in. As far as the eastern part of India is concerned,
here was no study of different apolipoproteins lev-
ls, assessment of LDL particle size, and some ratios
f lipoproteins and apolipoproteins with the con-
entional risk factors in blood, which are connected
ith CHD.
We have, therefore, attempted to ﬁnd out the
ssociation of CHD with LDL particle size, ratios of
ifferent lipoproteins and apolipoproteins, as well
s different traditional risk factors and the diagnos-
ic performance of this newly proposed biomarker
n CHD compared against known lipid markers.
ence this investigation was undertaken to deter-
ine whether the ratios of different lipoproteins
nd apolipoproteins are associated with CHD and
lso whether apoB/apoAI ratio is better than the
holesterol ratios to predict CHD. So it is very
mportant to study the newly arisen biomarker
long with the conventional risk factors among
sian Indian population in the eastern part of
ndia.
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ethods
opulation description and sample
ollection
ll subjects are Indian adults (1) CHD group: 100
atients (86 male, 14 female) with typical angina
nd electrocardiographic study, tread mill test,
tress echo and echocardiographic evidence of
schemia or infarction, aged between 45 and 65
ears old. (2) Control group: 98 healthy age and
ex-matched subjects (86 male, 12 female) aged
etween 45 and 65 years. The controls comprised
he spouses, neighbors, and people from same
ork place of the patients, with the same socio-
ultural background, in whom the clinical history,
he objective search for signals of CHD, and the
lectrocardiographic as well as echocardiographic
xamination did not suggest the presence of that
isease. All patients and controls with ancestral
rigin were from the eastern part of India. The
resent study was conducted during the period of
ctober 2006—February 2007 at the out-patients
epartment and also with in-patients of NRS Med-
cal College & Hospital, Kolkata. The subjects of
he present study were part of a health examina-
ion between the Immunotechnology Section, Bose
nstitute, Kolkata and the Department of Cardiol-
gy, NRS Medical College & Hospital, Kolkata. The
nstitutional ethical committee approved the study
rotocol. Informed consent was obtained from the
articipants. The cardiologist completed a clinical
uestionnaire for each subject. Venous blood sam-
les (5ml) were collected in the morning at the
oint of medical check-up into a sterile tube after
12-h overnight fast and also before the patient
ook any lipid-lowering drugs. Any patients or con-
rols found to have taken any lipid-lowering drugs
ere excluded from the study. Serum was harvested
n the day of sample collection by centrifuga-
ion at 3000 rpm for 10min at room temperature
sing tabletop centrifuge (Remi Pvt. Ltd., Mum-
ai, India). Subsequently, the serum was divided
nto aliquots for determination of lipids, glucose,
poA1, apoB, and apoE analysis.
uestionnaires and clinical characteristics
uestionnaires were distributed at the time of
he medical check-up. Participants were ques-
ioned about smoking and about any use of
ipid-lowering medication. They were questioned
bout the amount of alcoholic beverage (coun-
ry liquor) drunk per day as well as number of
igarettes, or ‘‘biri’’ (a type of local cigarette)
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Table 1 Characteristic of Asian Indian population in Eastern part of India in the case and control group
Variable Case (N = 100) Control (N = 98) p-Value a
Age, year (mean, S.D.) 54.80 (8.60) 55.54 (9.73) Matched
Sex (n, %) Matched
Male 86 (86%) 86 (87.75%)
Female 14 (14%) 12 (12.25%)
Smoking 0.000
Yes 63 (63%) 27 (27.55%)
No 27 (27%) 71 (72.45%)
Hypertension 0.000
Yes 66 (66%) 13 (13.27%)
No 34 (34%) 85 (86.73%)
Alcohol 0.000
Yes 27 (27%) 12 (12.25%)
No 73 (73%) 86 (87.75%)
con
r
P
L
p
G
v
L
LWaist circumference (cm) 88.75 (7.15)
a Mann—Whitney test for comparisons between the case and
smoked per day. Information about personal and
family history of cardiovascular disease, and risk
factors (hypertension) was obtained. Waist circum-
ference was measured just above the naval over
light clothing, using unstreatched tape meter, with-
out any pressure to body surface, and was recorded
to the nearest 0.1 cm.Blood biochemistry
Glucose was determined by using GOD-POD reagent
(Merck Ltd., Mumbai, India). TC was determined
enzymatically using CHOD/POD-Phosphotungstate
a
t
d
a
s
Table 2 The demographic information in CHD group and c
Variables CHD (n = 100)
Glucose (mg/dl) 90.91 (29.89)
Total cholesterol (mg/dl) 191.37 (36.42)
LDL-c (mg/dl) 124.45 (33.28)
HDL-c (mg/dl) 29.03 (6.33)
NonHDL-c (mg/dl) 162.17 (36.09)
TG (mg/dl) 188.61 (52.38)
apoA1 (mg/dl) 119.69 (21.90)
apoB (mg/dl) 114.74 (16.14)
apoE (mg/dl) 4.14 (0.72)
LDL-c/HDL-c 4.44 (1.42)
TC/HDL-c 6.80 (1.73)
TG/HDL-c 6.78 (2.90)
apoB/ApoA1 0.99 (0.24)
apoB/HDL-c 4.13 (1.02)
LDL-c/apoB 1.09 (0.29)
HDL-c/apoAI 0.25 (0.07)
NonHDL-c/HDL-c 5.80 (1.73)
LDL particle size (nm) 24.60 (1.02)
a Non paired Student’s t-test for comparisons between the mean85.42 (5.17) 0.000
trol group.
eagent. HDL-c was determined with CHOD/POD-
hosphotungstate reagent (Accurex Biomedical Pvt.
td., Mumbai, India), after precipitation with
hosphotungstic acid. TG was determined using
OP-POD reagent (Accurex Biomedical). Besides
alues of LDL-c was estimated using the formulae
DL-c = TC− (HDL-c + FTG/5) [16]. Determination of
DL particle size is based on the method of Krauss
nd Burke using gradient polyacrylamide gel elec-
rophoresis [17]. Apolipoprotein AI, B, and E were
etermined by immunoturbidimetry method using
uto N ‘‘DAIICHI’’ reagent and for standard mea-
urement using Apo auto N ‘‘DAIICHI’’ calibrator.
ontrol groups (mean, S.D.)
Control (n = 98) p-Valuea
81.06 (18.46) 0.006
161.11 (32.11) 0.000
99.97 (28.22) 0.000
34.18 (7.66) 0.000
126.93 (31.34) 0.000
134.77 (48.04) 0.000
129.79 (22.49) 0.002
89.06 (15.88) 0.000
4.11 (0.70) 0.769
3.10 (1.45) 0.000
4.94 (1.71) 0.000
4.19 (1.98) 0.000
0.69 (0.13) 0.000
2.73 (0.82) 0.000
1.15(0.39) 0.213
0.27 (0.07) 0.056
3.94 (1.71) 0.000
25.59 (0.67) 0.000
value of case and control groups.
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Table 3 Area under the receiver operating characteristic curve (AUROC) for different variables
Variables AUROC Standard error p-Value 95% CI
Glucose 0.591 0.042 0.029 0.508—0.673
TC 0.767 0.035 0.000 0.699—0.836
LDL-c 0.743 0.036 0.000 0.673—0.814
HDL-c 0.721 0.037 0.000 0.577—0.864
NonHDL-c 0.800 0.033 0.000 0.735—0.865
TG 0.798 0.032 0.000 0.737—0.860
apoAI 0.623 0.040 0.003 0.545—0.700
apoB 0.885 0.023 0.000 0.840—0.931
apoE 0.519 0.042 0.644 0.437—0.601
LDL-c/HDL-c 0.806 0.032 0.000 0.743—0.868
TC/HDL-c 0.835 0.030 0.000 0.777—0.893
TG/HDL-c 0.835 0.029 0.000 0.777—0.893
NonHDL-c/HDL-c 0.835 0.030 0.000 0.777—0.893
apoB/apoAI 0.882 0.023 0.000 0.838—0.927
apoB/HDL-c 0.882 0.025 0.000 0.833—0.931
LDL-c/apoB 0.504 0.042 0.914 0.423—0.586
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wHDL-c/apoAI 0.599 0.04
LDL particle size 0.860 0.02
or these measurements we used Microlab 2000
emi-auto analyzer (Merck Ltd.).
tatistical analysis
fter the completion of each experiment, the data
ere recorded on pre-designed proforma and man-
ged with Microsoft Excel software. Data entry
as double checked for any human error. All cal-
ulations were performed using SPSS version 10.0
oftware package for windows and MedCalc soft-
f
c
m
o
Table 4 Optimal cut-off value, sensitivity, speciﬁcity, and p
values (NPV) of different variables
Variables Cut-off Sensitivit
WC (cm) 85 0.680
Glucose (mg/dl) 100 0.313
TC (mg/dl) 175 0.724
LDL-c (mg/dl) 108 0.694
HDL-c (mg/dl) 30 0.626
NonHDL-c (mg/dl) 140 0.775
TG (mg/dl) 150 0.786
apoAI (mg/dl) 121 0.500
apoB (mg/dl) 100 0.830
apoE (mg/dl) 3.95 0.490
LDL-c/HDL-c 3.40 0.765
TC/HDL-c 5.30 0.806
TG/HDL-c 4.91 0.816
NonHDL-c/HDL-c 4.42 0.806
apoB/apoA1 0.80 0.790
apoB/HDL-c 3.07 0.879
LDL-c/ApoB 1.04 0.520
HDL-c/apoAI 0.24 0.566
LDL particle size (nm) 25.5 0.6630.016 0.520—0.678
0.000 0.806—0.914
are were used for comparison between the area
nder the receiver operating characteristic curve.
ata are presented as means (S.D.) and percent-
ge of the population studied. Student’s t-test (for
arametric variables) and Mann—Whitney U-test
for non-parametric variables) were used where it
as applicable to estimate the signiﬁcance of dif-
erence between two groups. Receivers operating
haracteristic (ROC) curves were used to deter-
ine the optimal cut-off values of these ratios
f lipoprotein and apolipoproteins. The points of
ositive predictive values (PPV) and negative predictive
y Speciﬁcity PPV NPV
0.531 0.596 0.620
0.877 0.720 0.558
0.755 0.747 0.732
0.684 0.687 0.691
0.724 0.697 0.657
0.765 0.767 0.773
0.673 0.706 0.758
0.673 0.610 0.569
0.734 0.761 0.808
0.479 0.490 0.479
0.704 0.721 0.750
0.724 0.745 0.789
0.745 0.762 0.802
0.776 0.782 0.800
0.735 0.752 0.774
0.694 0.743 0.850
0.469 0.495 0.494
0.574 0.574 0.566
0.910 0.880 0.739
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Table 5 Univariate logistic regression analysis of dif-
ferent markers in CHD
Variables Odds ratio 95% CI p-Value
Smoking 4.47 2.45—8.16 0.000
WC 2.40 1.34—4.28 0.003
Hypertension 12.69 6.20—25.95 0.000
Alcohol intake 2.65 1.25—5.60 0.009
Glucose 3.26 1.56—6.83 0.001
TC 8.10 4.27—15.36 0.000
LDL-c 4.89 2.67—8.96 0.000
HDL-c 4.40 2.41—8.04 0.000
NonHDL-c 11.26 5.78—21.92 0.000
TG 7.56 3.98—14.35 0.000
apoAI 2.06 1.15—3.66 0.013
apoB 13.52 6.79—26.90 0.000
apoE 0.880 0.50—1.54 0.669
LDL-c/HDL-c 7.75 4.10—14.67 0.000
TC/HDL-c 10.93 5.60—21.34 0.000
TG/HDL-c 12.97 6.54—25.71 0.000
NonHDL-c/HDL-c 14.36 7.20—28.63 0.000
apoB/apoA1 10.41 5.39—20.11 0.000
apoB/HDL-c 16.43 7.83—34.47 0.000
LDL-c/apoB 0.960 0.541—1.682 0.886
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iHDL-c/apoAI 1.73 0.981—3.50 0.054
LDL particle size 20.85 9.32—46.63 0.000
convergence of sensitivity and speciﬁcity deter-
mined the optimal cut-off points for these risk
factors. Then all the continuous variables were
dichotomized. Independent indicators for the pres-
Figure 1 Receiver-operating characteristic curve for the
prediction model of coronary heart disease. The ROC
curve was drawn from the equation that was calcu-
lated by logistic regression and is as follows: disease [yes
or no] = 1.085 apoB + 1.421 apoB/HDL-c + 1.689 nonHDL-
c + 1.849 apoB/apoAI + 2.262 LDL particle size− 11.702.
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nce of CHD were also selected by a forward
tepwise conditional logistic regression analysis. In
his method, the lipid and non-lipid parameters
ere selected into the model in the order of statis-
ical signiﬁcance. For all odds ratios, we calculated
5% conﬁdence intervals (CIs) of each variable and
ssociation study was done with Pearson 2-test.
ssociation of variables having p < 0.05 was consid-
red as statistical signiﬁcance. All statistical tests
f hypothesis are two sided.
esults
e studied a total of 198 subjects, of which
00 patients had CHD [86 male (86%) and 14
emale (14%)], mean (S.D.) age 54.80 (8.60) years
nd 98 age and sex-matched healthy controls
86 male (87.75%) and 12 female (12.25%)] mean
S.D.) age 55.54 (9.73) (Table 1). Smoking, alco-
ol consumption, hypertension and increased waist
ircumference were highly prevalent in the group
ith CHD as compared to control group (Table 1).
he mean value of TC and LDL-c were signiﬁcantly
igher in CHD patients compared with controls, but
he mean value of HDL-c was signiﬁcantly lower
n CHD patients than controls. We also observed
hat the mean value of TG and blood glucose
evels was higher in CHD patient than the con-
rol group (Table 2). Whereas the mean ratio of
DL-c/HDL-c, TC/HDL-c, TG/HDL-c and nonHDL-
/HDL-c were higher among CHD patients compared
o controls and all the results were statistically
ighly signiﬁcant (Table 2). Among the apolipopro-
eins, mean value of apoB was higher in patients
ompared to controls and value of apoAI was just
everse of it and both the values were statistically
ighly signiﬁcant, on the other hand mean value of
poE was similar in patients and controls and the
alue was statistically insigniﬁcant. But the ratio
f apoB/apoAI was highly signiﬁcant and the mean
alue was higher in CHD patients compared to the
ontrol group (Table 2). Among the studied ratios,
ome are, e.g. apo B/HDL-c shown to be statis-
ically signiﬁcant. On the contrary LDL-c/apo B,
DL-c/apoA1 ratios are lower in CHD patients but
re statistically insigniﬁcant.
Diagnostic implications of ratios of different
ipoproteins and apolipoproteins against the lipids
nd apolipoprotein markers were assessed by ROC
urves analysis. The analysis demonstrated that
poB (AUROC 0.885), apoB/apoAI (AUROC 0.882),
nd apoB/HDL-c (AUROC 0.882) were shown to
ave superior discriminative ability for CHD against
he other parameters (Table 3). There was no
tatistically signiﬁcant difference found in AUROC
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Table 6 Multivariate logistic regression analysis
Independent variables Regression coefﬁcient Odds ratio 95% CI p-Value
apoB 1.085 2.96 1.02—8.54 0.045
apB/HDL-c 1.421 4.14 1.33—12.83 0.014
NonHDL-c 1.689 5.41 2.08—14.10 0.000
apoB/apoAI 1.894 6.64 2.37—18.57 0.000
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etween these three variables. In Table 4 optimal
ut-off value, sensitivity, speciﬁcity, positive pre-
ictive value (PPV) and negative predictive value
NPV) of different parameters are shown.
Among the categorical variables, hypertension
ad 12 times higher odds ratio in patients than
ontrols and increased risk for CHD. The data in
able 5 indicate the risk of CHD of conventional
isk factors along with the different lipoprotein
nd apolipoprotein ratios and LDL particle size. In
he present study it was observed that those with
DL particle size less than 25.5 nm have risks of
HD 20 times higher than those with LDL particle
ize more than 25.5 nm. The risk for the ratio of
poB/HDL-c, nonHDL-c/HDL-c, TG/HDL-c, TC/HDL-
, apoB/apoAI and LDL-c/HDL-c are 16 times, 14
imes, 12 times, 10 times, 10 times and 7 times
igher in disease than control group, respectively.
ut the odds ratios of LDL-c/apoB and HDL-c/apoAI
re not signiﬁcant. Among the conventional risk fac-
ors the risk of apoB and nonHDL-c are 13 and 11
imes higher in CHD patients than controls.
Regression models were used to predict the
alue of a response variable using the dichotomized
xplanatory variables. From the univariate logistic
egression analysis 15 potential clinical predictors
f CHD were evaluated (Table 5). But in the ﬁnal
redictions model (Fig. 1) only ﬁve of these fac-
ors: the presence of nonHDL-c (OR 5.41; p = 0.001),
poB (OR 2.96; p = 0.045), apoB/apoAI (OR 6.64;
= 0.000), apoB/HDL-c (OR 4.41; p = 0.014) and
DL particle size (OR 9.59; p = 0.000) were found
Table 6). Area under the ROC curves derived
rom the multivariate model (AUROC 0.947; 95%
I 0.916—0.977) were statistically signiﬁcantly
igher than nonHDL-c (p < 0.001), apoB (p = 0.019),
poB/apoAI (p = 0.009), apoB/HDL-c (p = 0.009) and
DL particle size (p = 0.001).iscussion
he exact etiology of CHD is unknown; a large
umber of risk factors are known to be associated
ith CHD. Obesity [18], hypertension [19], smok-
a
m
1
m9.59 2.92—31.54 0.000
ng [20,21], family history [22], diabetes mellitus
23], and plasma lipoprotein abnormalities [23] are
he conventional risk factors of this disease. But in
ur knowledge, limited studies have been under-
aken to investigate the relationship between the
atios of different lipoproteins and apolipoproteins
nd LDL particle size with CHD in the Asian Indian
opulation in eastern part of India.
The aim of this study was to identify patients
ith early CHD associated with the conventional
isk factors and some of the new risk biochem-
cal markers, including apolipoprotein variables,
DL particle size, in addition to ratios of differ-
nt lipoproteins and apolipoproteins. These ratios
re chosen because human physiological systems
eed all the lipoproteins as well as apolipopro-
eins but it has certain limits. When these limits
ross, the systems face a lot of problems. So the
uman physiological systems need to balance all the
ood and bad things. However, here we considered
atios of different lipoproteins and apolipoproteins
evels such as LDL-c/HDL-c, TC/HDL-c, TG/HDL-c,
onHDL-c/HDL-c, apoB/apoAI, apoB/HDL-c, LDL-
/apoB and HDL-c/apoAI are important factors for
iagnosis of premature CHD.
The relevant ﬁndings in early CHD were as fol-
ows: hypertension, waist circumference, alcohol
onsumption and smoking were statistically highly
igniﬁcant with the CHD. Abnormal levels of lipids
nd apolipoproteins characterize the patients with
arly CHD who had a type of dyslipidemia with
n increase in atherogenic lipoproteins and apoB,
ower levels of HDL-c and apoAI. According to
asunaga et al. moderate drinking reduces the
ncidence of cardiovascular events [24], but in
ur study we found that 27% and 12.25% among
otal number of patients and controls, respectively,
ere drinking country liquor per day, and the data
how alcohol intake is signiﬁcantly associated with
HD (Table 1). A study by Stamler et al. found a
trong association between serum cholesterol, CAD
nd cardiovascular death [6]. Gandhi reported that
ean serum TC level was 160mg/dl in males and
50mg/dl in females [25]. Our study shows that
ean TC in patients is 191.37mg/dl and the con-
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trol group is 161.11mg/dl. LDL-c is the strongest
predictor of CHD and some studies show that the
disease is closely correlated with high concentra-
tions of TC and LDL-c [7]. Natio reported a high
incidence of atherosclerosis and CHD in subjects
with LDL-c above 130mg/dl [26]. In our study we
have observed that an elevated level of LDL-c is
associated with CHD. The high concentrations of
TC and LDL-c in patients means that they are 8
and 4 times more at risk than those with normal
concentrations, respectively. Numerous epidemi-
ological studies from North America and Europe
have conclusively demonstrated that high levels of
HDL-c protect against CHD [11]. According to Stain
and Myers HDL-c below 35mg/dl was associated
with atherosclerosis and CHD [27]. Another group
showed that low HDL-c or smoking is more likely
to result in myocardial infarction [28]. But in our
observation we have found that below 30mg/dl
HDL-c concentrations is a risk for CHD in the eastern
part of the Indian population. According to Wiklund
et al. TG level above 200mg/dl is a risk for CHD [8].
In our study, hypertriglyceridemia alone was not
observed in the group with early CHD. However, the
ratio of LDL-c to HDL-c or TC to HDL-c is accepted
as an extremely important indicator of atherogen-
esis [11]. In consideration of these, we also studied
the relationship of these ratios with CHD, and found
that these ratios are highly signiﬁcantly associ-
ated with CHD, as found by other groups [29]. The
American Diabetes Association (64th Scientiﬁc Ses-
sion, 2004, Orlando, FL, USA) proposed apoB/HDL-c
ratio as the predictor of atherosclerotic disease.
We observed that the ratio of apoB/HDL-c and
HDL-c is strongly associated with CHD risk among
Asian Indian populations in the eastern part of
India. According to Maruyama et al. concentration
of small dense LDL is positively associated with
TG/HDL-c ratio [30]. In our study, we observed that
the ratio of TG to HDL-c is higher in CHD patients
compared to the control group. Several studies have
related the higher level of apoB and lower level of
apoAI to the early occurrence of CHD. We observed
that apoAI concentration is lower and apoB con-
centration is higher in the CHD group than controls
as found in other studies [13]. A large number of
epidemiological studies have identiﬁed small dense
LDL as an independent risk factor for CHD [31]
which is often associated with both hypertriglyc-
eridemia and low HDL-c. However, several reports
have shown that a higher LDL-c/apoB ratio iden-
tiﬁes subjects with predominantly large buoyant
LDL particles, whereas a lower value will point to
predominantly small dense LDL particles [32—35].
Increase in serum apoB may suggest a large num-
ber of LDL particles in blood circulation [10]. We
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bserved that in patients, increased LDL-c is associ-
ted with increased apoB levels. LDL-c to apoB ratio
as less than 1.2 in CHD patients found by one group
36], but in our study we observed that in both CHD
atients and controls the ratio of LDL-c to apoB is
ess than 1.2 though the concentration is higher in
ontrol groups than CHD patients. The apoB/apoAI
atio represents the balance of proatherogenic and
ntiatherogenic lipoproteins and also identiﬁes the
ipoprotein related risk of vascular disease [37].
owever, the ratio of apoB/apoAI was signiﬁcantly
igher in CHD patients than controls, and it is asso-
iated with the disease. According to Sposito et al.
DL-c to apoAI ratio was signiﬁcantly lower in a
iver failure group than controls [38]. In our study,
e also found that HDL-c to apoAI ratio is lower in
HD patients than controls, but the difference is
ot statistically signiﬁcant.
The ROC curve, which is deﬁned as a plot of
est sensitivity versus its 1-speciﬁcity was used
o describe and compare the performance of
he diagnostic test. The AUROC for apoB/apoAI,
poB/HDL-c, LDL particle size, TC/HDL-c and
onHDL-c/HDL-c are greater than other biochem-
cal markers (except apoB) suggesting that these
ay provide a better discriminating test for CHD.
nd also the difference between the AUROC
or apoB and apoB/apoAI (p = 0.832), apoB/HDL-c
p = 0.832), LDL particle size (p = 0.516), TC/HDL-
(p = 0.118) and nonHDL-c/HDL-c (p = 0.118) were
ot statistically signiﬁcant. But from these ratios
poB to apoAI ratio is equivalent or better pre-
ictive than other lipoprotein and apolipoprotein
atios for screening of CHD? The results were eval-
ated by ROC curves. Table 3 shows that the ratio
f apoB to apoAI and apoB to HDL-c are the best
iscriminators on the basis of ROC curve analysis.
hough at a cut-off point sensitivity of apoB/HDL-
showed 11.26% higher rate than apoB/apoAI
Table 4) and in Table 5, the odds ratio is 16.43
or ratio of apoB to HDL-c and 10.41 for ratio of
poB to apoAI that deﬁnes a 57% difference. So,
rom the above analysis it is concluded that apoB
o apoAI ratio is a good predictive marker for CHD,
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poB, apoB/HDL-c, nonHDL-c, apoB/apoAI and LDL
article size are contributed in this model. The
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hat the overall model ﬁt is good. The model using
onHDL-c, apoB, apoB/apoAI, apoB/HDL-c and LDL
article size to predict the probability of being a
ase or control in the study sample categorized 89
f 100 cases (89%) and 86 of 98 controls (87.75%)
imilarly. AUROC derived from the model was statis-
ically signiﬁcantly higher from any other variables.
o, this model (Fig. 1) is the best discriminator
or CHD. We included patients with acute myocar-
ial infarction (AMI), unstable angina and stable
ngina in our study. We classiﬁed the cases of
MI considering WHO and American Heart Associ-
tion criteria [39]; unstable angina consistent with
raunwald clinical classiﬁcation [40]. The patients
ith stable angina were determined by clinical his-
ory, ECG changes and corroborative evidence of
he treadmill test, as well as stress echocardiog-
aphy. Atherosclerosis and unstable plaque is the
ajor contributory factor for CAD. We have a limi-
ation in our study regarding the estimation of the
xtent and burden of atherosclerosis by doing coro-
ary angiography and multidetector row computed
omography.
Several strengths are present in our study. First,
he case—control study has several advantages over
ther designs, especially, a cohort study. Second,
asting bloods were collected enabling valid deter-
ination of HDL-c, LDL-c, TG, TC, glucose and
polipoproteins. Third, our study included several
isk factors that have previously not been assessed
ith conventional risk factors, which might be the
est marker of the balance of atherogenic and
ntiatherogenic particles. In conclusion, since in
he world, there is vast ethnic and cultural hetero-
eneity, future investigations should be undertaken
n other populations to determine the relative
ole of our regression equation (Fig. 1) based
n nonHDL-c, apoB, apoB/apoAI, apoB/HDL-c and
DL particle size, which may be useful as mark-
rs for diagnosis of predisposition to CHD in a
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